REQUOLIS Trademark

Trademark Overview


On Wednesday, September 19, 2012, a trademark application was filed for REQUOLIS with the United States Patent and Trademark Office. The USPTO has given the REQUOLIS trademark a serial number of 85732531. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 6, 2016. This trademark is owned by Novartis AG. The REQUOLIS trademark is filed in the Pharmaceutical Products category with the following description:

(Based on Intent to Use) Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use ...
requolis

General Information


Serial Number85732531
Word MarkREQUOLIS
Filing DateWednesday, September 19, 2012
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 6, 2016
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 5, 2013

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and Services(Based on Intent to Use) Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in dermatology; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceuticals, namely, anti-infectives(Based on 44(e)) Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in dermatology; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceuticals, namely, anti-infectives

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, September 22, 2012
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNovartis AG
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBasel
CH

Party NameNovartis AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBasel
CH

Trademark Events


Event DateEvent Description
Monday, June 6, 2016ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, June 6, 2016ABANDONMENT - NO USE STATEMENT FILED
Friday, October 23, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 22, 2015EXTENSION 5 GRANTED
Tuesday, October 20, 2015EXTENSION 5 FILED
Tuesday, October 20, 2015TEAS EXTENSION RECEIVED
Wednesday, May 6, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 5, 2015EXTENSION 4 GRANTED
Monday, April 27, 2015EXTENSION 4 FILED
Monday, April 27, 2015TEAS EXTENSION RECEIVED
Thursday, October 30, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 29, 2014EXTENSION 3 GRANTED
Monday, October 27, 2014EXTENSION 3 FILED
Monday, October 27, 2014TEAS EXTENSION RECEIVED
Friday, May 9, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 8, 2014EXTENSION 2 GRANTED
Wednesday, April 16, 2014EXTENSION 2 FILED
Tuesday, May 6, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, April 16, 2014TEAS EXTENSION RECEIVED
Wednesday, October 16, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 14, 2013EXTENSION 1 GRANTED
Monday, October 14, 2013EXTENSION 1 FILED
Monday, October 14, 2013TEAS EXTENSION RECEIVED
Tuesday, April 30, 2013NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 5, 2013OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 5, 2013PUBLISHED FOR OPPOSITION
Wednesday, February 13, 2013NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, January 30, 2013LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, January 30, 2013ASSIGNED TO LIE
Thursday, January 17, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 10, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 10, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 10, 2013TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Saturday, December 22, 2012NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Saturday, December 22, 2012LETTER OF SUSPENSION E-MAILED
Saturday, December 22, 2012SUSPENSION LETTER WRITTEN
Friday, December 21, 2012ASSIGNED TO EXAMINER
Saturday, September 22, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, September 22, 2012NEW APPLICATION ENTERED IN TRAM